• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>NuVasive

NuVasive

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. UPDATE: S&P 500 survives test of 50-day -2-

    UPDATE: S&P 500 survives test of 50-day -2-

  2. UPDATE: S&P 500 survives test of 50-day average amid technical cross currents

    UPDATE: S&P 500 survives test of 50-day average amid technical cross currents

  3. UPDATE: Charting the U.S. stock markets' bearish near-term technical tilt

    UPDATE: Charting the U.S. stock markets' bearish near-term technical tilt

  4. UPDATE: Charting the U.S. stock markets' -2-

    UPDATE: Charting the U.S. stock markets' -2-

  5. UPDATE: Charting the March cross currents, S&P 500 presses support ahead of the Fed

    UPDATE: Charting the March cross currents, S&P 500 presses support ahead of the Fed

  6. UPDATE: Charting the March cross currents, S&P -2-

    UPDATE: Charting the March cross currents, S&P -2-

  7. UPDATE: S&P 500 challenges the breakout point amid (still) bullish longer-term backdrop

    UPDATE: S&P 500 challenges the breakout point amid (still) bullish longer-term backdrop

  8. UPDATE: S&P 500 challenges the breakout point -2-

    UPDATE: S&P 500 challenges the breakout point -2-

  9. $145.8 Million Stem Cell Therapy Market by Type, Therapeutic Application, Cell Source - Global Forecasts to 2021 - Research and Markets

    $145.8 Million Stem Cell Therapy Market by Type, Therapeutic Application, Cell Source - Global Forecasts to 2021 - Research and Markets

  10. United States Market Overview for Orthopedic Biomaterials 2017: Unit Sales, ASPs, Market Value & Growth Trends - Research and Markets

    United States Market Overview for Orthopedic Biomaterials 2017: Unit Sales, ASPs, Market Value & Growth Trends - Research and Markets

12

©2017 Morningstar Advisor. All right reserved.